ASTRO Virtual Meeting Center

Dr. Gerold Bepler is the Department Chair of Thoracic Oncology and the Director of the Comprehensive Lung Cancer Research Center at Moffitt Cancer Center in Tampa, Fla. Prior to joining Moffitt, he served as the Director of the Lung Cancer Program at Roswell Park Cancer Institute, with joint appointments in the Department of Medicine and the Department of Cancer Genetics. While enrolled in the Medicine Residency and Hematology/Oncology Training Programs at Duke University Medical Center, Dr. Bepler was selected as Chief Medical Resident as a result of his outstanding medical knowledge, patient care and leadership skills. Dr. Bepler established an independent research career in July 1994, and headed the laboratory of molecular cancer epidemiology at Duke for five years. His bibliography includes 113 publications with focus on lung cancer. Dr. Bepler serves as a reviewer for many international journals, including New England Journal of Medicine, JAMA, JCO, Journal of the National Cancer Institute, Cancer Research and others. He has received NIH grants for over 10 years and is a reviewer for several NIH study sections.

David R. Gandara, MD, professor of medicine at the University of California, Davis School of Medicine is Associate Director of Clinical Research and Director of Thoracic Oncology at the University of California, Davis Cancer Center. He is a diplomat of the American Board of Internal Medicine specializing in Medical Oncology. He is currently principal investigator for a number of research projects in lung cancer, pharmacology trials at various phases, and Southwest Oncology Group trials. He is the principal investigator for a National Cancer Institute award to the California Cancer Consortium for Early Therapeutic Trials of New Anti-Cancer Agents. He is chair of the Southwest Oncology Group (SWOG) Lung Committee, and was co-chair, and continues to be a member, of the NCI-directed Investigational Drug Steering Committee. He has written over 300 articles, book chapters, abstracts and editorials. He is editor-in-chief of Clinical Lung Cancer, serves on the editorial board of four oncology journals, and is a manuscript reviewer for eight additional journals. He also serves as President-elect and on the board of directors for the International Association for the Study of Lung Cancer (IASLC) and is a prior board member and secretary-treasurer of the American Society for Clinical Oncology (ASCO). He also is chair of the NCI-directed Lung Correlative Science Committee. After receiving his medical degree from the University of Texas Medical Branch in Galveston, Dr. Gandara was an intern and resident at the Madigan Army Medical Center in Tacoma and a fellow at the Letterman Army Medical Center Presidio of San Francisco.

Corey J. Langer, MD, FACP, who is board certified in internal medicine, hematology and oncology, is a Professor of Medicine in Medical Oncology at the University of Pennsylvania, Abramson Cancer Center, where he directs the Thoracic Oncology program. Prior to 2008, he was an Attending Physician in Medical Oncology at Fox Chase Cancer Center (FCCC) and Medical Director of Thoracic Oncology there from 1994 until 2008. Dr Langer received his medical degree from Boston University in 1981 and completed his Internship and Residency in medicine at The Graduate Hospital of the University of Pennsylvania in Philadelphia in 1984. Additional postgraduate training included a Fellowship in Hematology/Oncology at the Presbyterian-University of Pennsylvania Medical Center and a Fellowship in Oncology at AOH / Fox Chase Cancer Center, which he completed in 1987. Dr Langer is a Fellow of the American College of Physicians and is a member of the American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH), American Association for Cancer Research (AACR), International Association for the Study of Lung Cancer (ISLAC), and the Society of Head and Neck Surgeons. He serves as Vice-Chair of the Radiation Therapy Oncology Group (RTOG) and as Chair of its Medical Oncology Subcommittee. He also serves on the core Thoracic and Head and Neck Committees of both the Eastern Cooperative Oncology Group (ECOG) and RTOG. Dr Langer is Chair of the Commission on Cancer Head and Neck Cancer Database Committee under the aegis of the American Cancer Society and the American College of Surgeons. While at FCCC, he served as the Research Chair of the Oncology Physicians Network, a consortium of academic and community facilities in the Delaware Valley dedicated to clinical trials. In addition, he served as Chair of the Pharmacy and Therapeutics Committee and Quality Management Committee at FCCC for nearly 20 years. Dr Langer has contributed numerous articles and abstracts to the medical literature. His work on head and neck squamous cell cancer and non-small cell lung cancer has appeared in The New England Journal of Medicine, Seminars in Oncology, Clinical Cancer Research, the JNCI, Journal of Clinical Oncology, Cancer, Lung Cancer, Cancer Investigation, Clinical Lung Cancer and EJC. Dr Langers work has also been presented at the national meetings of ASCO, AACR, ASTRO, ASH, and the IASLC. He has served three separate terms as a member of the Editorial Board of the JCO and is currently on the Editorial Boards of Clinical Lung Cancer and Clinical Advances in Hematology and Oncology. While at FCCC, he served on the NCCN NSCLC, and SCLC committees. He has reviewed articles for JCO, Clinical Lung Cancer, CCR, Cancer, Annals of Oncology and Lung Cancer, and the Journal of Thoracic Oncology. He is also a frequent lecturer at numerous medical symposia and Grand Rounds.

Over the last 15 years Dr. Scagliotti�s research interests included experimental studies on basic and clinical applied research on lung cancer, including translational research. He has been and currently is the study coordinator of several European and international clinical trials on lung cancer chemotherapy and he has been a key investigator in several Italian studies investigating the role of chemotherapy in early stage non-small cell lung cancer. Dr. Scagliotti is a member of numerous scientific societies, including the Italian Society of Respiratory Medicine, the European Respiratory Society, the American Society of Clinical Oncology and the International Association for the Study of Lung Cancer. From 2002 to 2005 he was member of the International Affair Committee of the American Society of Clinical Oncology and from 2003-07 Executive Board member of the International Association for the Study of Lung Cancer. He is currently serving on the Publication Committee and Program Committee of the American Society of Clinical Oncology. Dr. Scagliotti is a manuscript reviewer for 11 scientific journals. He currently serves on the editorial boards of Critical Review in Oncology and Hematology, and Oncology News. He is Associate Editor for Journal of Thoracic Oncology and International Editor for Clinical Lung Cancer. He is the author or co-author of more than 180 publications in peer-reviewed journals.